Liu et al. [37] described a new targeted therapy comprising an anti-PD-L1 conjugate and miR-424-loaded nanobubbles that was tested in subcutaneous mouse hepatocellular carcinoma. The gene discussed is CD274; the disease is hepatocellular carcinoma.